A clinicopathological study of lung adenocarcinoma specimens showed that low GPX4 expression was an independent poor prognostic factor, while high FSP1 expression was associated with significantly better prognosis in terms of RFS. This evidence concerns the gene GPX4 and lung adenocarcinoma.